Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
This comparison of intermittent versus extended-infusion piperacillin-tazobactam among patients with Gram-negative infections revealed similar mortality and length of stay. Outcomes remained similar when stratified by MIC value.
Patel
Gita Wasan
GW
Medical Center of Plano, TX 75075, USA.
Patel
Nimish
N
Lat
Asma
A
Trombley
Kristen
K
Enbawe
Sam
S
Manor
Kelli
K
Smith
Raymond
R
Lodise
Thomas P
TP
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D007902:Length of Stay; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010878:Piperacillin / Q000008:administration & dosage* / Q000627:therapeutic use; D000078142:Tazobactam; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin